(“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the launch of a study to determine the levels ...

Plenitude Trial initiated Tetra completes clinical study assessing the metabolism profile of cannabinoids in humans Achieved development of ARDS-003 sterile injectable nano-emulsion for human use ...

("Tetra" or the "Company") (TSX VENTURE:TBP)(TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter ...

By combining our capabilities and focusing our resources to generate the right drug for the right patient, the Tetra/Altus joint venture overcomes many of the hurdles that have dogged cannabinoid ...

Tetra's PPP003 cannabinoid drug receives Orphan Drug Designation for the Prevention of Proliferative Vitreoretinopathy OTTAWA / ACCESSWIRE / April 15, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the ...

The Danish biotech company, Tetra Pharm Technologies, is launching its first product, XATEPA, on the German market. XATEPA is a pain-relieving pharmaceutical drug based on cannabinoids. "The ...

It has completed mapping of human cannabinoids and metabolites during 3Q 2020, which will have a major impact on both the development of QIXLEEF and CAUM Tetra projects completion in 2020 of the ...

OTTAWA, ONTARIO--(Marketwired - Feb. 4, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(TBPMF), a global leader in cannabinoid-based drug development and discovery, is ...

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return ...

However, the chemical structures of their unique active components — the cannabinoids — were not elucidated until the 1960s. Three decades later, the first solid clues on cannabinoid molecular ...